PCI Biotech Holding ASA (FRA:4QG) Accounts Payable & Accrued Expense : €0.13 Mil (As of Jun. 2024)

View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Accounts Payable & Accrued Expense?

PCI Biotech Holding ASA's quarterly accounts payable & accrued expense declined from Jun. 2023 (€0.21 Mil) to Dec. 2023 (€0.14 Mil) and declined from Dec. 2023 (€0.14 Mil) to Jun. 2024 (€0.13 Mil).

PCI Biotech Holding ASA's annual accounts payable & accrued expense declined from Dec. 2021 (€0.54 Mil) to Dec. 2022 (€0.16 Mil) and declined from Dec. 2022 (€0.16 Mil) to Dec. 2023 (€0.14 Mil).

PCI Biotech Holding ASA Accounts Payable & Accrued Expense Historical Data

The historical data trend for PCI Biotech Holding ASA's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Accounts Payable & Accrued Expense Chart

PCI Biotech Holding ASA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

1.33

0.69

0.54

0.16

0.14

PCI Biotech Holding ASA Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23	Jun24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															0.16	0.02	0.21	0.14	0.13

PCI Biotech Holding ASA Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

PCI Biotech Holding ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (FRA:4QG) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

PCIB:Norway

Address

Ullernchausseen 64, Oslo, NOR, N-0379

Website

https://www.pcibiotech.com

PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines